Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells

The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2(V617F) mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition of Stathmin 1 activity via STAT3. In support of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Machado-Neto, João Agostinho, de Melo Campos, Paula, Favaro, Patricia, Lazarini, Mariana, da Silva Santos Duarte, Adriana, Lorand-Metze, Irene, Costa, Fernando Ferreira, Olalla Saad, Sara Teresinha, Traina, Fabiola
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745747/
https://ncbi.nlm.nih.gov/pubmed/26356819
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados